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Abstract. Features of impact of hyperferritinemia in combination with hyperuricemia on the course of gout. 
Kuzmina G.P., Lazarenko O.M. The purpose of the study is to find out the frequency of development of hyperfer-
ritinemia in combination with hyperuricemia in patients with gout, to assess their pathogenetic significance and to 
outline their role in the development of joint syndrome, to identify informative prognostic criteria. 72 patients with gout 
were examined. The 1st (main) group included 37 patients with gout with hyperuricemia combined with hyper-
ferritinemia, whose mean age (SD) was 55.9 (10.7) years. Group 2 (comparison group) included 35 patients with gout 
and hyperuricemia and normal levels of ferritin (mean age - 52.8 (4.8) years). Group 3 (control) group included 20 
practically healthy individuals (mean age 52.0 (2.9) years). The average level of blood uric acid was significantly dif-
ferent (p=0.0254) in the main group and the comparison group and amounted to 464.5 (122.5) μmol/L and 403.8 
(403.8; 403.8), respectively. The value of ferritin in the main group was significantly higher 410.2 (356.2; 415.2), 
p<0.01) ng/mL, than in the comparison group (132.1 (20.5) ng/mL, as well as the values of the urine uric acid and C-
reactive protein values (hs-CRP) (p=0.0001) 8.2 (6.0; 8.2) and 5.8 (6.1) mg/L, respectively. A direct reliable cor-
relation was established (r=0.30; p<0.05) between the level of blood uric acid and ferritin, the duration of gout 
(r=0.41; p<0.05), the total number of affected joints (r=0.35; p<0.03), the severity of gout (r=0.36; p<0.05), as well as 
between the level of ferritin and the number of exacerbations of gout (r=0.44; p<0.05). Hyperferritinemia in com-
bination with hyperuricemia is found in 51.0% of patients with gout, significantly worsening the course of the 
inflammatory process Patients with gout and high levels of ferritin, unlike patients with normal levels of ferritin, have 
the following clinical anamnestic signs: greater number of exacerbations of gout per year, duration of gout and last 
outbreak of gout, exacerbation of arthritis, total number of affected joints, pain intensity during exacerbation by scale 
VAS. In patients with gout, the severity of the course and the form of gouty arthritis, which are determined according to 
imaging methods (erosion, peripheral and bone tophus, the sign of "double contour", the degree of narrowing of the 
joint gaps and the severity of subchondral sclerosis), have prognostic significance. The association of ferritin with 
blood uric acid in gout does not depend on the level of hs-CRP. 
 
Резюме. Особливості впливу гіперферитинемії у сполученні з гіперурикемією на перебіг подагри. 
Кузьміна Г.П., Лазаренко О.М. Мета дослідження – з'ясувати частоту розвитку гіперферитинемії у сполу-
ченні з гіперурикемією в пацієнтів на подагру, оцінити їх патогенетичну значущість та окреслити роль при 
розвитку суглобового синдрому, виділити інформативні прогностичні критерії. Було обстежено 72 пацієнти з 
подагрою. До 1-ї (основної) групи увійшли 37 пацієнтів на подагру з гіперурикемією, поєднаною з гіпер-
феритинемією, середній вік (SD) яких становив 55,9 (10,7) року. До 2-ї групи (група порівняння) увійшли 35 па-
цієнтів, що страждають на подагру  з гіперурикемією та нормальним рівнем феритину  (середній вік – 52,8 
(4,8) року). До 3-ї (контрольної) групи увійшло 20 практично здорових осіб (середній вік 52,0 (2,9) року). 
Середній показник рівня сечової кислоти крові достовірно відрізнявся (р=0,0254) в основній групі та групі 
порівняння і становив 464,5 (122,5) мкмоль/л та 403,8 (403,8; 403,8) відповідно. Значення феритину в основній 
групі достовірно вище 410,2 (356,2; 415,2), р<0,01) нг/мл, ніж у групі порівняння (132,1 (20,5) нг/мл, як і 
значення сечової кислоти сечі та високочутливого С-реактивного протеїну (hs-СРП) (р=0,0001) 8,2 (6,0; 8,2) і 
5,8 (6,1) мг/л відповідно. Між рівнем сечової кислоти крові та феритину у пацієнтів І групи був виявлений 
прямий, середній, достовірний кореляційний зв'язок (r=0,30; р<0,05), крім того достовірний кореляційний 
зв'язок виявлено між рівнем сечової кислоти крові та тривалістю подагри (r=0,41; р<0,05), загальною 
кількістю уражених суглобів (r=0,35; р=0,03), ступенем тяжкості подагри (r=0,36; р<0,05), а також між 
рівнем феритину та кількістю спалахів подагри (r=0,44; р<0,05). Гіперферитинемія у сполученні з гіперу-
рикемією виявляється в 51,0% пацієнтів з подагрою, суттєво погіршуючи перебіг запального процесу. 
Пацієнтам з подагрою та високим рівнем феритину, на відміну від хворих з нормальним рівнем феритину, 
притаманні такі клініко-анамнестичні ознаки: більша кількість загострень подагри на рік, тривалість 
подагри та останнього спалаху подагри, тривалість та вираженість артриту при загостренні, загальна 
кількість уражених суглобів, інтенсивність больового синдрому при загостренні за шкалою VAS. У пацієнтів з 
подагрою тяжкість перебігу і форма подагричного артриту, які визначаються згідно з методами візуалізації 
(ерозії, периферичні та кісткові тофуси, ознака «подвійного контуру», ступінь звуження суглобових щілин та  
вираженість субхондрального склерозу), мають прогностичну значущість. Асоціація феритину з сечовою 
кислотою крові при подагрі не залежить від рівня hs-СРП. 
 
The prevalence of gout has recently increased in 
all countries of the world, reaching >6% in the 
population, with gouty arthritis remaining in the 
position of the most common type of arthritis among 
men [8]. 
According to modern ideas, the basis of inflam-
mation are changes in homeostasis of iron. Serum 
ferritin is a biomarker of the inflammatory process. 
Uric acid acts as an iron chelator, on the one hand, 
modeling the activity of xanthine oxidase, and on the 
other – affecting its synthesis. According to the 
NHANES (USA) study, ferritin is positively asso-
ciated with uric acid, and high ferritin levels increase 
the risk of hyperuricemia [7, 9]. It is the combination 
of such components that form the complex of uric 
acid iron crystals‚ through the activation of granular 
cells and the complement system contributes to the 
development of a gout exacerbation. Increase in 
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serum ferritin is today interpreted solely as a sign of 
iron overload. Ferritin is not only a depot of iron, it 
is also a positive protein in the acute phase of 
inflammation. A number of authors point out that 
ferritin is a marker of even a hyper-inflammatory 
reaction in which its level rapidly increases in the 
short time. The so-called hemophagocytic syndrome 
(HPS) associated with hyperferritinemia even threa-
tens patients' lives. Based on the above, it is reported 
that serum ferritin is a sufficiently sensitive and 
specific marker of inflammation. Due to the cyto-
kine storm and uncontrolled activation conditions, 
the capture of iron by macrophages is increased and 
its export to erythropoiesis is impaired. Activation of 
macrophages and impaired iron export from it is a 
leading factor in the inflammatory process. Such a 
massive immune response contributes to the loss of 
cytotoxicity by T-lymphocytes. Therefore, it should 
be noted that macrophages initiate the inflammation 
process, both in the joint cavity and phagocytate 
monosodium urate crystals (MSU) and participate in 
ferritin-MSU complexation. Macrophages then crea-
te a framework for the formation of specific pro-
teins, so-called inflammasomes in the cytoplasm of 
the macrophage. Inflammasomes are a high mole-
cular weight protein complex that triggers the me-
chanisms of transformation of inactive pro-inter-
leukin-1β (pro-IL-1β) into biologically active IL-1β, 
which is subsequently released from the cell [1, 4]. 
It is known that iron is mainly a component of 
proteins, among which there are those that directly 
bind iron. The amount of iron released from the 
enterocytes into the bloodstream is regulated by 
enhancing or attenuating the synthesis of the protein 
apoferritin (ferritin containing no iron)‚ which stores 
iron by transforming it into ferritin and retaining it 
internally in cells. When the iron enters the blood, its 
transport is carried out by the protein of the blood-
transfevoin. An iron exchange regulator is hepcidin, 
which is capable of both blocking and enhancing 
iron homeostasis. Ferritin is involved in the acute 
phase of inflammation, even during the pre-immune 
response. The acute phase response is a complex 
defense that is aimed at a qualitative immune res-
ponse. To effectively promote iron, cells of the 
reticuloendothelial system (KES) enhance ferritin 
synthesis, which is accompanied by the influence of 
pro-inflammatory cytokines, first of all, IL-1 and IL-
6. Studies have shown that ferritin rich in the H-
subunits plays a significant role in the acute phase 
response, as it is able to capture iron faster‚ than the 
more stable L-ferritin. It is the first protects that cells 
from radicals. On this basis, cells are able to regulate 
the amount of H-ferritin contained in them by 
secreting it into the plasma, thus getting rid of 
residues that lead to excessive iron uptake. It is 
possible that this is the main reason for the increase 
of plasma ferritin during the response in the 
outbreak of gouty arthritis. Prolonged circulation of 
proinflammatory cytokines leads to iron retention in 
RES cells and iron overload in ferritin composition. 
In this case, ferritin is gradually transformed into 
hemosiderin, which not only has a protective effect, 
but also damages the cells. The latter degrades very 
slowly, but at the same time binds iron firmly, 
breaking its secretion [5, 6, 10, 14]. 
In recent years, there has been an increasing 
interest in studying the mechanisms of iron meta-
bolism in gout, which is accompanied by an increase 
in ferritin level, whose clinical and pathogenic 
significance has not been fully elucidated in gout. 
The role of uric acid and ferritin in the development 
of oxidative stress is being studied [15]. 
In tophus removed surgically, synovia and iron 
are detected in ionized form, which, in combination 
with MSU crystals, is a factor in exacerbation of 
gouty arthritis. The resulting iron-MSU complex 
leads to the activation and release of the cascade of 
proinflammatory cytokines, which are the main 
pathogenetic link of the inflammatory process in 
gout [11, 14]. 
The purpose of the study is to find out the 
frequency of development of hyperferritinemia in 
combination with hyperuricemia in patients with 
gout, to assess their pathogenetic significance and to 
outline the role in the development of joint synd-
rome, to identify informative prognostic criteria. 
MATERIALS AND METHODS OF RESEARCH  
The research was carried out at the clinical basis 
of the Department of Therapy, Cardiology and 
Family Medicine of Faculty of Postgraduate Edu-
cation of the State Establishment "Dnipropetrovsk 
Medical Academy of Health Ministry of Ukraine" in 
the seltings of the MNE "Сenter for primary health 
care N 4" of Kryvyi Rih City Council, and further 
examination was carried out in the Municipal Enter-
prise «Kryvyi Rih City Clinical Hospital N 2» of Kry-
vyi Rih City Council in the period from 2016 to 2018.  
Permission was obtained from the Commission 
on Biomedical Ethics of the State Establishment 
“Dnipropetrovsk Medical Academy of Health Mi-
nistry of Ukraine” (protocol N 1 of January 16, 
2017) the scientific research was approved, the work 
was in accordance with generally accepted standards 
of morality, the requirements of observance of 
rights, interests and personal dignity of research 
participants, there is no risk to research subjects 
while performing the work, laboratory and instru-
mental research methods are generally accepted and 
the drugs to be used are approved. 
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72 patients with gout were examined. The first 
(main) group included 37 patients with gout with 
hyperuricemia combined with hyperferritinemia, 
whose average age was 55.9 (10.7) years. Group 2 
(comparison group) included 35 patients with gout 
and hyperuricemia with normal levels of ferritin 
(average age – 52.8 (4.8) years). Group 3 (control) 
included 20 practically healthy individuals (average 
age 52.0 (2.9) years). 
The average age of gout manifestation in group 1 
was 49.6 (10.2) years (28 to 65 years). The duration 
of the disease ranged from 1 to 17 years (median – 
6.0 (4.0; 8.0) years). In patients in group 2, gout 
developed at the age of 47.2 (8.7) years (36 to 65 
years), and the median of disease duration was 4.0 
(2.0; 6.0) years (1 to 14 years). 
The diagnosis of gout was established according 
to the criteria of the American College of Rheu-
matology and the the European Anti-rheumatic 
League (2015) [12]. The diagnosis of hypertension 
was established in accordance with the order of the 
Ministry of Health of Ukraine N 384 dated May 24, 
2012, in accordance with the recommendations of 
the Ukrainian Association of Cardiology and the 
clinical recommendations of the European Society 
of Hypertension and the European Society of 
Cardiology (2018) [3, 13]. Clinical and anamnestic 
data of all patients were taken, an analysis of the 
previous medical documentation, laboratory and 
instrumental research methods was carried out. 
Main inclusion criteria: patients with gout and 
hyperuricemia (blood uric acid level for male 
>420.0 μmol/L, for female >360.0 μmol/L) combined 
with hyperferritinemia (ferritin level >400.0 ng/mL) 
who gave informed consent to participate in the 
study; patients with gout and normal levels of 
ferritin who gave informed consent to participate in 
the study; patients aged 30-65 years. 
Exclusion criteria: patients who did not give 
consent to participate in the study; patients who 
abuse alcohol or narcotic drugs; patients with can-
cer, psychiatric and rheumatologic diseases, 
diseases of the blood system, other crystalline 
arthropathies; cardiac insufficiency of ІІB-ІІІ sta-
ge, functional class IV, chronic kidney disease of 
ІV-V stage; viral hepatitis, tuberculosis, HIV-
infected patients. 
All patients with gout were given allopurinol at a 
starting dose of 100 mg per day, followed by 
titration of the dose once a month and determination 
of blood uric acid level to reach the target blood uric 
acid level <360.0 μmol/L. In exceeding the reference 
levels of ferritin >400.0 ng/mL deferoxamine was 
administered alternate days 500 mg per day to reach 
the target level of ferritin within 100.0-200.0 ng/mL. 
Determination of the level of ferritin was carried 
out by immunochemical method with electro-
chemiluminescent detection, using the Cobas 6000 
analyzer and the Roche Diagnostics test system 
(Switzerland). Determination of blood uric acid 
concentration was carried out by means of colorimetric 
analysis, urinary uric acid – by spectrophotometric 
method, SRP – by the immune enzyme method. 
Methods of mathematic-statistical analysis of 
research materials were used: verification of normal 
distribution of quantitative indicators using the 
Shapiro-Wilk test; assessment of the reliability of 
the difference in mean for quantitative attributes 
with the normal distribution according to the 
Student's t-test; an abnormal distribution Mann-
Whitney (U) test for unrelated samples; the proba-
bility of the difference in relative indices using the 
Pearson Chi-Square (χ2) test, including the Yates 
correction for values of the index close to 0 or 100. 
Comparisons of the three independent groups were 
performed using the Kruskal-Wallis One-Way 
Analysis of Variance (nonparametric tests algo-
rithms). A correlation analysis was carried out with 
the calculation of the Spearman's Rank Correlation 
Coefficient (ρ), multiple regression analysis. 
Descriptive statistics results were presented in the 
form of mean (M) and standard deviation (SD) for 
values with normal distribution and in the form of me-
dian (Me) and interquartile range (Q25; Q75) for para-
meters with the distribution that differs from normal. 
P-values of <0.05 were determined to represent 
statistical significance. The statistical analysis was 
carried out using the Microsoft Excel 2010, data 
analysis program AtteStat 12.0.5, and Statistica 6.1 
(StatSoft Inc.). 
RESULTS AND DISCUSSION 
The duration of gout averaged 4.0 (2.5; 7.0) years, 
the age of disease debut was 48.4 (9.5) years, the 
number of exacerbations of gout per year – 5.0 (4.0; 
5.0), the total number of affected joints – 5.5 (2.0; 
12.0), the duration of the last exacerbation of gout 
over the last year – 16.0 (14.0; 17.0) days, the dura-
tion of arthritis – 15.0 (14.0; 16.0) days. The first 
sign of gout in 97.2% (70) of patients was a joint 
inflammation and in 2.8% (2) – renal colic. Articular 
pathology in 77.6% (56) cases debuted with arthritis 
of the first metatarsal joints, 15.2% (11) – of ankle, 
4.2% (3) – of knee. The incidence of intermittent 
arthritis was 22.2% (16) and chronic – 77.8% (56). 
Peripheral tophus was found in 13.9% (10), bone – 
in 34.7% (25), metabolic syndrome was diagnosed 
in 93.1% (67) of observations. 
The duration of hypertension in patients with 
gout was 6.0 (3.0; 9.0) years. Hypertension debut 
was 48.2 (46.0; 52.0) years. The number of 
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exacerbations of hypertension per year is 4.0 (3.0; 
5.0). The average level of systolic blood pressure 
(SBP) was 145.0 (140.0; 150.0) mm Hg, diastolic 
blood pressure (DBP)- 90.0 (87,5; 100.0) mm Hg. 
By stages of hypertension patients were divided as 
follows: stage I was registered in 7 (9.7%) patients, 
stage II – in 63 (87.5%), III – in 2 (2.8%) patients. 1 
degree of hypertension was detected in 47 (65.3%) 
patients, 2 – in 20 (27.8%), 3 – in 5 (6.9%) patients. 
Hyperuricemia at the time of examination 
>360 µmol/L was established in 81.9% (59) of cases, 
low uraturia (<2200 µmol/L) – in 19.4% (14), metabo-
lic type of impaired purine metabolism was in 12.5% 
(9), renal – in 20.8% (15), mixed – in 66.7% (48). 
 
T a b l e  1  
Main characteristics of groups, M (SD), Me (25%; 75%) 
Indicator, units of measurement Main group (n=37) Comparison group (n=35) Control group (n=20) р 
Gender: male, n (%) 36 (97.3) 30 (85.7) 16 (80.0) р=0.09** 
р=0.08†† 
р=0.59‡‡ 
Age, years 55.9 (10.7) 52.8 (4.8) 52.0 (2.9) р=0.11** 
р=0.07†† 
р=0.29‡‡ 
The clinical stage, n (%) 
- acute gouty arthritis; 
- intermittent gouty arthritis; 
- chronic gouty arthritis; 
- chronic tophaceous arthritis 
 
1 (2.7) 
5 (13.5) 
24 (64.9) 
7 (18.9) 
 
1 (2.9) 
9 (25.7) 
22 (62.9) 
3 (8.6) 
 
 
 
 
- 
 
р=0.97†† 
р=0.19†† 
р=0.86†† 
р=0.20†† 
Radiological stage of the disease, n (%) 
- no changes 
- І 
- ІІ 
- ІІІ 
 
4 (10.8) 
9 (24.3) 
23 (62.2) 
1 (2.7) 
 
6 (17.1) 
17 (48.6) 
10 (28.6) 
2 (5.7) 
 
- 
 
р=0.65†† 
р=0.03† 
р=0.01† 
р=0.83†† 
functional insufficiency of the joints, n (%) 
- absent 
- І 
- ІІ 
 
3 (8.1) 
19 (51.4) 
15 (40.5) 
 
9 (25.7) 
22 (62.9) 
4 (11.4) 
 
 
- 
 
р=0.04† 
р=0.41†† 
р=0.03† 
Note: * – Significant difference between the main and control group, † – Significant difference between the main and comparison group, ‡ – 
Significant difference between the comparison and control group, ** – There is no significant difference between the main and control group, †† – 
There is no significant difference between the main and comparison group, ‡‡ – There is no significant difference between the comparison and 
control group. 
 
In patients of group I (main), acute gouty arthritis 
was established in 1 (2.7%) patient, intermittent gouty 
arthritis – in 5 (13.5%), chronic gouty arthritis – in 24 
(64.9%), chronic tophaceous arthritis – in 7 (18.9%), 
and in group II (comparison) – 1 (2.9%), 9 (25.7%), 22 
(62.9%), 3 (8.6%), respectively, Table 1. 
In the radiological stage of the disease, patients 
in group I were divided as follows: no changes – 4 
(10.8%), stage I – 9 (24.3%), II – 23 (62.2%), III – 1 
(2.7%), and in group II – the following data: 6 
(17.1%), 17 (48.6%), 10 (28.6%), 2 (5.7%), res-
pectively. There was no functional insufficiency of 
the joints in 3 (8.1%), stage I – in 19 (51.4%), stage 
II – in 15 (40.5%) patients compared with patients 
with normal ferritin level – 9 (25.7%), 22 (62.9%), 4 
(11.4%), respectively. That is, among the patients in 
the main group, there is a high proportion of patients 
with a more severe course of gout, as well as with 
marked changes in the radiograph and a higher 
degree of functional insufficiency of the joints than 
in the comparison group. 
The general characteristics of the groups are 
shown in Table 2. The average level of blood uric 
acid was significantly different (p=0.0254) in the 
main group and the comparison group and amounted 
to 464.5 (122.5) µmol/L and 403.8 (403.8; 403.8), 
respectively. The value of ferritin in the main group 
was significantly higher 410.2 (356.2; 415.2), 
p<0.01) ng/mL, than in the comparison group 132.1 
(20.5) ng/mL, as well as C-reactive protein values 
(hs-CRP) (p=0.0001) 8.2 (6.0; 8.2) and 5.8 
(6.1) mg/L, respectively. Values of urine uric acid 
differed significantly (p=0.0028) in both groups and 
amounted to 2509.0 (630.6) μmol/L in the main 
group and 2408.5 (2193.0; 2469.0) μmol/L in the 
comparison group. It should be noted that statis-
tically significant difference and lower values of 
laboratory parameters in the control group were 
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registered compared to the main group and patients 
with gout and normal ferritin level. 
Patients with gout and high levels of ferritin, 
unlike patients with normal levels of ferritin, have 
the following clinical anamnestic signs: greater 
number of exacerbations of gout per year (р=0.002), 
duration of gout (р=0.008), duration of the last 
exacerbation of gout (р=0.005), duration of arthritis 
in exacerbation (р=0.003), total number of affected 
joints (р=0.03), pain intensity during exacerbation 
by scale VAS (р=0.03). There was no significant 
difference between the groups regarding the age of 
gout debut (p=0.25). 
 
T a b l e  2  
Clinical and laboratory characteristics of patients in the main,  
control and comparison groups, M (SD), Me (25%; 75%) 
Indicator, units of measurement Main group (n=37) Comparison group (n=35) 
Control group 
(n=20) р 
Ferritin, ng/mL 410.2 (356.2; 415.2) 132.1 (20.5) 113.5 (60.4) р<0.01* 
р<0.01† 
р=0.0002‡ 
Blood uric acid, μmol/L 464.5 (122.5) 403.8 
(403.8; 403.8) 
281.9 (63.5) р<0.01* 
р=0.0254† 
р<0.01‡ 
Uric acid in urine, μmol/L 2509.0 (630.6) 2408.5 (2193.0; 2469.0) 
 
2114.1 (547.2) р=0.0002* 
р=0.0028† 
р=0.0003‡ 
hs-СRP, mg/L 8.2 (6.0; 8.2) 5.8 (6.1) 1.0 (0.0; 2.9) 
 
р<0.01* 
р=0.0001† 
р<0.01‡ 
The number of exacerbations of gout 
per year 
5.0 (5.0; 5.0) 4.0 (4.0; 6.0) - р=0.04† 
Duration of gout, years 6.0 (4.0; 8.0) 4.0 (2.0; 6.0) - р=0.008† 
Gout debut age, years 49.6 (10.2) 47.2 (8.7) - р=0.25 
Duration of the last exacerbation of 
gout, days 
16.0 (16.0; 17.0) 14.0 (12.0; 16.0) - p<0.01† 
Duration of arthritis with 
exacerbation, days 
15.0 (15.0; 16.0) 14.0 (13.0; 16.0) - р=0.004† 
Total number of joints affected 8.0 (4.0; 14.0) 2.0 (2.0; 12.0) - р=0.03† 
Exacerbation by VAS scale, mm 41.0 (16.0) 30.0 (30.0; 40.0) - р=0.03† 
Note: * – Significant difference between the main and control group, † – Significant difference between the main and comparison group, ‡ – 
Significant difference between the comparison and control group, †† – There is no significant difference between the main and comparison group. 
 
A direct, moderate, significant correlation 
(r=0.30; p<0.05) was found in the main group 
between blood uric acid and ferritin, and a significant 
correlation was found between blood uric acid and du-
ration of gout (r=0.41; p<0.05), total number of affec-
ted joints (r=0.35; p=0.03), severity of gout (r=0.36; 
p<0.05), as well as between the level of ferritin and the 
number of gout outbreaks (r=0.44; p<0.05). 
We have analyzed the relationship between fer-
ritin and hs-CRP in patients with gout. In group I, 
high levels of ferritin were accompanied by 
significantly higher levels of hs-CRP than in patients 
in group II. In our view, both hs-CRP and ferritin 
may participate in separate pathogenesis links in 
gout patients. However, ferritin and hs-CRP were 
not risk factors for hyperuricemia. Both levels were 
significantly elevated in patients with gout. Of 
course, the increase in the level of ferritin and hs-
CRP can be explained by the development of chro-
nic inflammatory process in gout, but recent studies 
indicate that the association of ferritin with uric acid 
and gout is independent of the level of hs-CRP [6]. 
Iron exchange rates and excessive deposition of 
MSU crystals affect the severity and form of gouty 
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arthritis, the nature of bone-destructive signs (inclu-
ding erosions) of articular syndrome, the presence of 
peripheral and bone tophus. 
Exacerbation of gouty arthritis was accompanied 
by mono-articular lesions of foot joints (especially 
the first metatarsal joints) or ankle joints; rapid onset 
of severe pain (by VAS scale activity reaching values 
of varying severity) and swelling of the joints (within 
24 hours), erythema, synovitis. 
In the lesion of the first metatarsal foot joints in 
patients with gout accompanied by hyperfer-
ritinemia in combination with high levels of uric 
acid, according to ultrasound diagnostics of the 
joint, lesions of the surrounding soft tissues, 
synovitis, and in some patients – tophus were 
revealed. Half of the patients of group I and one 
third of group II reported the deposition of MSU 
crystals on the surface of the cartilage of the joint 
as a "double contour" sign. 
The association between hyperferritinemia and 
hyperuricemia was accompanied by a more pro-
nounced outbreak of gouty arthritis. It can be assu-
med that high level of ferritin not only enhances the 
formation of uric acid, but also promotes the crys-
tallization of MSU. The latter is confirmed by the 
presence of MSU crystals in the synovial fluid 
aspirate, as well as by imaging diagnostic methods 
for finding the deposition of MSU crystals (ultra-
sound, dual-energy computed tomography - DECT). 
Chronic tophaceous arthritis according to radio-
graphic examination of the joints was characterized 
by the soft tissue compaction, the presence of 
erosion, periarticular deposition of MSU crystals. 
Tissue edema, granulomatous response to MSU crys-
tals were located both intra- and extra-articularly. 
In patients with gout the combination of 
hyperuricemia with hyperferritinemia is closely 
associated with the severity of joint syndrome 
(p<0.01), the degree of narrowing of the joints gaps 
(p<0.05), the severity of subchondral sclerosis 
(p<0.05), the development of erosions (p<0.05), 
which have prognostic significance as revealed by 
multiple regression analysis. 
All patients with gout received allopurinol star-
ting with a dose of 100 mg monthly, determining the 
level of blood uric acid and increasing the dose of 
allopurinol by 100 mg to reach the target level of 
blood uric acid <360 µmol/L. On average, reaching 
the target uric acid level in patients in the main 
group occurred in 4 (3; 4) months, and in the 
comparison group – in 3 months at an average dose 
of allopurinol 300 (268; 300) mg in both groups. 
In exacerbations of gout, colchicine was admi-
nistered at a starting dose of 1 mg on the first day, 
then 0.5 mg in hour, on day 2 – 0.5 mg three times a 
day. Supportive therapy for patients in remission 
was performed with colchicine at a preventive dose 
(0.5 mg per day) to reduce the risk of exacerbation. 
Separate studies have shown possible random 
connections between iron and the frequency of 
gout outbreaks. It is suggested that even the 
exclusion of iron-rich food can help to prevent 
gout outbreaks [14]. 
Complex therapy for patients in both groups 
included antihypertensive drugs (Figure): angio-
tensin II receptor blocker and angiotensin-converting 
enzyme inhibitors: 18 (48.6%) received losartan and 
19 (51.4%) – ramipril; beta-blockers: bisoprolol – 
3 (8.1%), nebivolol – 2 (5.4%), carvedilol – 2 (5.4%); 
calcium channel blockers: amlodipine – 21 (56.8%), 
lercanidipine – 4 (10.8%); nonthiazide diuretics – 
indapamide 7 (18.9%). Acetylsalicylic acid was 
prescribed to 21 (56.8%) patients and clopidogrel – 
2 (5.4%) patients as antithrombotic agents. All 
patients with gout were prescribed atorvastatin at a 
starting dose of 20 mg daily and subsequent dose 
titration (40, 60 mg) according to lipidograms. That 
is, the selected drug groups are in line with the 
recommendations of the European League Against 
Rheumatism (2016), i.e. patients with gout and 
comorbid hypertension were prescribed losartan and 
calcium antagonists, and in hyperlipidemia statins 
were given preference. 
If the reference levels of ferritin >400.0 ng/mL 
are exceeded, the preparation of deferoxamine was 
administered 500 mg on alternate days to reach the 
target level of ferritin within 100.0-200.0 ng/mL. An 
analysis of treatment efficacy in patients with 
hyperferritinemia during a gout outbreak showed a 
significant improvement in the overall condition 
(halving the VAS pain intensity) after the first 
injection of deferoxamine. Course treatment with the 
use of the drug deferoxamine in the complex therapy 
of gouty arthritis among patients of group I (1500-
2000 mg) reduced the serum ferritin level to the 
target level (100.0-200.0 ng/mL), and was more 
effective (reducing the period of joint syndrome to 7 
days) than in patients in the comparison group 
(duration of joint syndrome – 14 days). At the same 
time, the visualization data were changing, namely 
the disappearance of the "double contour" sign 
according to the ultrasound data, which indicated a 
regression of changes related to the deposition of 
urate in the joints. In addition, ultrasound imaging 
clearly showed the disappearance of synovitis and 
resorption of doughy tophus by the 7th day. In the 
comparison group, this process was longer and 
affected the period of restoration of the functional 
state of the joints. 
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The main groups of antihypertensive drugs prescribed to the patients with gout 
 
CONCLUSIONS 
1. Hyperferritinemia in combination with hyperu-
ricemia is found in 51.0 % of patients with gout, 
significantly worsening the course of the inflam-
matory process Patients with gout and high levels of 
ferritin, unlike patients with normal levels of ferritin, 
have the following clinical anamnestic signs: greater 
number of exacerbations of gout per year, duration 
of gout, and last exacerbation of arthritis, for total 
number of affected joints, pain intensity during 
exacerbation by scale VAS.  
2. In patients with gout, the severity of the course 
and the form of gouty arthritis, which are determined  
 
according to imaging methods (erosion, peripheral 
and bone tophus, the sign of "double contour", the 
degree of narrowing of the joint gaps and the 
severity of subchondral sclerosis), have prognostic 
significance.  
3. Increased levels of ferritin and hs-CRP in gout 
patients are factors that are involved in the deve-
lopment of inflammation but are not personally risk 
factors for hyperuricemia.The association of ferritin 
with blood uric acid in gout does not depend on the 
level of hs-CRP. 
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